Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Bio Path Holdings Inc (NASDAQ:BPTH)

0.38
Delayed Data
As of Jul 21
 -0.0146 / -3.70%
Today’s Change
0.33
Today|||52-Week Range
1.75
-71.85%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$36.3M

Company Description

Bio-Path Holdings, Inc. operates as a biotechnology company which focuses on the development of targeted therapies for acute myeloid leukemia, chronic myeloid leukemia, and other types of cancer. Its drug candidates include prexigebersen and Liposomal Bcl2. The company was founded by Peter Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein, and Ana Maria Tari on May 10, 2007 and is headquartered in Bellaire, TX.

Contact Information

Bio-Path Holdings, Inc.
4710 Bellaire Boulevard
Bellaire Texas 77054
P:(832) 742-1357
Investor Relations:
(832) 742-1369

Employees

Shareholders

Mutual fund holders4.45%
Individual stakeholders16.53%
Other institutional15.45%

Top Executives

Peter H. NielsenChairman, President, CEO, CFO & Treasurer
Ulrich W. MuellerChief Operating Officer & Secretary
Anthony PriceDirector-Finance & Accounting
Tara SadeghiDirector-Clinical Operations
William F. HahneVice President-Clinical Research